A Phase 2, Three-arm, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol (PH94B) Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Fasedienol (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors VistaGen Therapeutics
Most Recent Events
- 12 Feb 2025 New trial record